INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)

Project Summary: pending


  • Scott D. Solomon, MD, Harvard Medical School
  • Orly Vardeny, PharmD, MS, University of Wisconsin - Madison

PaTH Protocol PI(s):

  • Kathleen McTigue, MD, University of Pittsburgh
  • Anuradha Paranjape, MD, MPH, FACP, Lewis Katz School of Medicine at Temple University, Temple Health

Purpose: Influenza leads to significant morbidity and mortality, particularly in patients with cardiovascular disease. High-dose influenza vaccine is FDA approved for use in medically stable adults over the age of 65 but has not been studied, nor is it indicated, for patients under the age of 65 or in those with chronic conditions.

Goal(s): To assess whether high-dose influenza vaccine compared with standard dose vaccine will reduce cardiopulmonary events in a high-risk cardiovascular population.

Study Design: Randomized Active-Control Double-Blind Comparative Multicenter Clinical Trial. The study sample will consist of adult patients without a previous history of intolerance to a standard dose of influenza vaccine. One group will receive standard dose trivalent, inactivated influenza vaccine (15 μg/strain, TIV), one group will receive a four-fold dose of TIV (60μg/strain). Each season, the same vaccine will be administered according to each participant’s assigned randomized therapy. Patients will be followed up to 12 months.

PCORnet Partners: pending

PaTH Partners:

  • University of Pittsburgh

Sponsor: Barbara Wells, National Heart, Lung, and Blood Institute

Coordinating Center: University of Wisconsin-Madison, Harvard Medical School, University of Toronto, Clinical Sciences Center, Madison, Wisconsin

Fact Sheet: pending

How to Participate: Participants will be recruited from sites in the United States and Canada through electronic health systems over three influenza seasons.

PaTH Network Logo
Twitter Logo Facebook Logo LinkedIn Logo YouTube Logo

Copyright 2016 | PaTH Network